Ligger ingenting mellom her:
Nordic Nanovector finally throws in the towel
Years behind schedule and on its seventh chief executive since 2016, Nordic Nanovector has finally admitted defeat with Betalutin in third-line follicular lymphoma. Concern about the progress of the Paradigme trial prompted a look at the data, which confirmed the worst: a profile that rendered the project, a CD37-targeted radionucleotide, irrelevant.


